Office of the Director, National Institutes of Health; Notice of Meeting, 31624-31625 [2012-12864]

Download as PDF 31624 Federal Register / Vol. 77, No. 103 / Tuesday, May 29, 2012 / Notices records retention burden to be minimal, as the Agency believes most establishments would normally keep this kind of record for at least several years after receiving the report, as a matter of usual and customary business practice. Dated: May 22, 2012. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2012–12878 Filed 5–25–12; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Dated: May 22, 2012. Reva Harris, Acting Director, Division of Policy and Information Coordination. Advisory Commission on Childhood Vaccines; Notice of Meeting srobinson on DSK4SPTVN1PROD with NOTICES In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting: Name: Advisory Commission on Childhood Vaccines (ACCV). Date and Time: June 14, 2012, 8:30 a.m. to 11:45 a.m. EDT. Place: Parklawn Building (and via audio conference call), Conference Room 10–65, 5600 Fishers Lane, Rockville, MD 20857. The ACCV will meet on Thursday, June 14 from 8:30 a.m. to 11:45 a.m. (EDT). The public can join the meeting via audio conference call by dialing 1–800–369–3104 on June 14 and providing the following information: Leader’s Name: Dr. Geoffrey Evans. Password: ACCV. Agenda: The agenda items for the June meeting will include, but are not limited to: updates from the Division of Vaccine Injury Compensation (DVIC), Department of Justice (DOJ), National Vaccine Program Office (NVPO), Immunization Safety Office (Centers for Disease Control and Prevention), National Institute of Allergy and Infectious Diseases (National Institutes of Health) and Center for Biologics, Evaluation and Research (Food and Drug Administration). A draft agenda and additional meeting materials will be posted on the ACCV Web site (https:// www.hrsa.gov/vaccinecompensation/ accv.htm) prior to the meeting. Agenda items are subject to change as priorities dictate. Public Comment: Persons interested in attending the meeting in person or providing an oral presentation should submit a written request, along with a copy of their presentation to: Annie Herzog, DVIC, Healthcare Systems Bureau (HSB), Health Resources and Services Administration (HRSA), Room 11C–26, 5600 Fishers Lane, Rockville, Maryland 20857 or email: aherzog@hrsa.gov. Requests should contain the name, address, telephone number, email address, and any business or professional affiliation of the person desiring to make an oral presentation. Groups having similar interests are requested to combine their VerDate Mar<15>2010 16:12 May 25, 2012 Jkt 226001 comments and present them through a single representative. The allocation of time may be adjusted to accommodate the level of expressed interest. DVIC will notify each presenter of their assigned presentation time by email, mail, or telephone. Persons who do not file an advance request for a presentation, but desire to make an oral statement, may announce it at the time of the public comment period. Public participation and ability to comment will be limited to space and time as it permits. For Further Information Contact: Anyone requiring information regarding the ACCV should contact: Annie Herzog, DVIC, HSB, HRSA, Room 11C–26, 5600 Fishers Lane, Rockville, MD 20857; telephone (301) 443– 6593; email: aherzog@hrsa.gov. [FR Doc. 2012–12849 Filed 5–25–12; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; 2012–10 K and R13 Review Teleconference. Date: June 25, 2012. Time: 9:30 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Rm. 951, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Ruixia Zhou, Ph.D., Scientific Review Officer, 6707 Democracy Boulevard, Democracy Two Building, Suite 957, Bethesda, MD 20892, 301–496–4773, zhour@mail.nih.gov. PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 Dated: May 21, 2012. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2012–12866 Filed 5–25–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Recombinant DNA Advisory Committee. Date: June 19, 2012. Time: 9:00 a.m. to 3:30 p.m. Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will discuss selected human gene transfer protocols. Please view the meeting agenda at https:// oba.od.nih.gov/rdna_rac/rac_meetings.html for more information. Place: National Institutes of Health, Building 31C, 9000 Rockville Pike, 6th Floor Conference Room, Rockville, MD 20892. Contact Person: Chezelle George, Office of Biotechnology Activities, Office of Science Policy/OD, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301–496–9838, georgec@od.nih.gov. OBA will again offer those members of the public viewing the meeting via webcast (see OBA Meetings Page available at https:// oba.od.nih.gov/rdna_rac/rac_meetings.html) the opportunity to submit comments during the public comment periods. Individuals wishing to submit comments should use the comment form, which will accommodate comments up to 1500 characters, and will be available on the OBA Web site during the meeting (see OBA Meetings Page). Please limit your comments to a statement that can be read in one to two minutes. Please include your name and affiliation with your comment. Only comments submitted through the OBA Web site will be read. OBA will read comments into the record during the public comment periods as stated on the agenda. It is not unusual for the meeting to run ahead or behind schedule due to changes in the time needed to review a protocol. It is advisable to monitor the webcast to determine when public comments will be read. Each public comment period follows a specific discussion item. OBA will E:\FR\FM\29MYN1.SGM 29MYN1 Federal Register / Vol. 77, No. 103 / Tuesday, May 29, 2012 / Notices srobinson on DSK4SPTVN1PROD with NOTICES read comments that are related to the protocol under discussion at that time. General comments unrelated to the protocol or presentation under discussion at that time. General comments unrelated to a specific agenda item will be read at the end of the meeting, time permitting. Comments submitted by email through the OBA Web site will follow any comments by individuals attending the meeting. Comments will be read in the order received and your name and affiliation will be read with the comments. Please note OBA may not be able to read every comment received in the time allotted for public comment. Comments not read will become part of the public record. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// oba.od.nih.gov/rdna/rdna.html, where an agenda and any additional information for the meeting will be posted when available. OMB’s ‘‘Mandatory Information Requirements for Federal Assistance Program Announcements’’ (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) VerDate Mar<15>2010 16:12 May 25, 2012 Jkt 226001 Dated: May 18, 2012. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2012–12864 Filed 5–25–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center For Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Clinical Neurophysiology, Devices, Neuroprosthetics, and Biosensors. Date: June 21–22, 2012. Time: 8:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: Radisson Salt Lake City Downtown, 215 West South Temple, Salt Lake City, UT 84101. Contact Person: Keith Crutcher, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5207, MSC 7846, Bethesda, MD 20892, 301–435– 1278, crutcherka@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Sensory Technologies. Date: June 21–22, 2012. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance Washington, DC Dupont Circle Hotel, 1143 New Hampshire Avenue NW., Washington, DC 20037. Contact Person: Paek-Gyu Lee, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4201, MSC 7812, Bethesda, MD 20892, (301) 613– 2064, leepg@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Biophysical, Physiological, Pharmacological and Bioengineering Neuroscience. Date: June 21–22, 2012. Time: 8:00 a.m. to 5:00 p.m. PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 31625 Agenda: To review and evaluate grant applications. Place: Marriott Bethesda Pooks Hill, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Joseph G. Rudolph, Ph.D., Chief and Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186, MSC 7844, Bethesda, MD 20892, 301–408– 9098, josephru@csr.nih.gov. Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group, Health Disparities and Equity Promotion Study Section. Date: June 21–22, 2012. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Lorien Hotel and Spa, 1600 King Street, Alexandria, VA 22314. Contact Person: Delia Olufokunbi Sam, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3158, MSC 7770, Bethesda, MD 20892, 301–435– 0684, olufokunbisamd@csr.nih.gov. Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group, Motor Function, Speech and Rehabilitation Study Section. Date: June 22, 2012. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Washington Marriott, 1221 22nd Street NW., Washington, DC 20037. Contact Person: Biao Tian, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3166, MSC 7848, Bethesda, MD 20892, 301–402–4411, tianbi@csr.nih.gov. Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group, Biostatistical Methods and Research Design Study Section. Date: June 22, 2012. Time: 9:00 a.m. to 9:00 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Inner Harbor, 301 W. Lombard St., Baltimore, MD 21201. Contact Person: Tomas Drgon, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3152, MSC 7770, Bethesda, MD 20892, 301–435– 1017, tdrgon@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR09–221: Innovations in Biomedical Computational Science and Technology Initiative. Date: June 22, 2012. Time: 3:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Radisson Salt Lake City Downtown, 215 West South Temple, Salt Lake City, UT 84101. Contact Person: Keith Crutcher, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5207, MSC 7846, Bethesda, MD 20892, 301–435– 1278, crutcherka@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR12–054: E:\FR\FM\29MYN1.SGM 29MYN1

Agencies

[Federal Register Volume 77, Number 103 (Tuesday, May 29, 2012)]
[Notices]
[Pages 31624-31625]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-12864]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: June 19, 2012.
    Time: 9:00 a.m. to 3:30 p.m.
    Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will 
discuss selected human gene transfer protocols. Please view the 
meeting agenda at https://oba.od.nih.gov/rdna_rac/rac_meetings.html 
for more information.
    Place: National Institutes of Health, Building 31C, 9000 
Rockville Pike, 6th Floor Conference Room, Rockville, MD 20892.
    Contact Person: Chezelle George, Office of Biotechnology 
Activities, Office of Science Policy/OD, National Institutes of 
Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301-496-
9838, georgec@od.nih.gov.
    OBA will again offer those members of the public viewing the 
meeting via webcast (see OBA Meetings Page available at https://oba.od.nih.gov/rdna_rac/rac_meetings.html) the opportunity to 
submit comments during the public comment periods. Individuals 
wishing to submit comments should use the comment form, which will 
accommodate comments up to 1500 characters, and will be available on 
the OBA Web site during the meeting (see OBA Meetings Page). Please 
limit your comments to a statement that can be read in one to two 
minutes. Please include your name and affiliation with your comment. 
Only comments submitted through the OBA Web site will be read.
    OBA will read comments into the record during the public comment 
periods as stated on the agenda. It is not unusual for the meeting 
to run ahead or behind schedule due to changes in the time needed to 
review a protocol. It is advisable to monitor the webcast to 
determine when public comments will be read. Each public comment 
period follows a specific discussion item. OBA will

[[Page 31625]]

read comments that are related to the protocol under discussion at 
that time. General comments unrelated to the protocol or 
presentation under discussion at that time. General comments 
unrelated to a specific agenda item will be read at the end of the 
meeting, time permitting. Comments submitted by email through the 
OBA Web site will follow any comments by individuals attending the 
meeting. Comments will be read in the order received and your name 
and affiliation will be read with the comments. Please note OBA may 
not be able to read every comment received in the time allotted for 
public comment. Comments not read will become part of the public 
record.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit. Information is also available on the Institute's/Center's 
home page: https://oba.od.nih.gov/rdna/rdna.html, where an agenda and 
any additional information for the meeting will be posted when 
available.

    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: May 18, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-12864 Filed 5-25-12; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.